Pfizer signs licensing deal with Starna Therapeutics for autoimmune disease treatments
PFE•Pfizer signed an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases. Starna will receive $330 million upfront and may earn up to $2.3 billion in milestones, plus royalties on approved products’ net sales.




